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Polyethyleneimines (PEIs) are a well-studied class of polymers.1,2 These polymers are
synthesized commercially via the ring opening of aziridine (Scheme 1, Reaction 2),3–5
although this process leads to highly branched polymers6 with significant polydispersity
indexes. The controlled synthesis of linear PEIs occurs via the cationic ring opening of
oxazolines,7–9 followed by hydrolysis of the resulting formamides (Scheme 1, Reaction 1).
Using chiral oxazolines as substrates for the polymerization reaction provides
straightforward access to homochiral PEIs,10–12 with chiral centers at every polymer repeat
unit.
The significant interest in PEIs is driven largely by various applications of PEIs in fields
including chiral catalysis,13–16 drug delivery,17,18 and oligonucleotide complexation and
delivery.19,20 PEIs have also been covalently linked to form PEI-derived microcapsules,21
which have been used for site-isolated catalysis.22,23 In one example, the Lewis basic PEI
catalyzed a reaction in the same reaction vessel as a Lewis acidic nickel catalyst, which was
used to catalyze the second reaction.24,25
Use of the same PEI scaffold for multiple applications has rarely been reported, although
such multi-purpose polymers would have significant operational advantages. Reported
herein is the use of a single PEI scaffold for two purposes: the fabrication of covalently-
linked chiral microcapsules, and the efficient delivery of siRNA to Huh7 cells.26
The chiral PEIs were synthesized via the cationic polymerization of 4-benzyl-2-oxazoline
(1a) (both R and S configurations), followed by the hydrolysis of the initially formed
polyformamide (Scheme 2). The resulting polymers were characterized by 1H NMR
spectroscopy, and the results were in agreement with literature-reported spectra.11 Using this
methodology, polymers with 13 and 30 repeat units were formed, with both R and S
configured side chains.
Once synthesized, the homochiral PEIs were cross-linked to form homochiral microcapsules
following the procedure developed by McQuade and co-workers.22 Briefly, polymers 2a
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were dissolved in methanol, and added to a solution of 2% Span 85, followed by the
addition of 2,4-tolylene diisocyanate (TDI, compound 7) (Equation 1), which cross linked
the microcapsules to form a polyurea coating.25 The resulting polyurethane-type structures
have been shown to be stable in a variety of aqueous media.27,28 After thorough solvent
evaporation, chiral microcapsules were obtained.
The resulting microcapsules were imaged using transmission electron microscopy (TEM),
and some images are shown in Figure 1. The diameters of the particles ranged from 57 nm–
250 nm, with an average diameter of 141 nm (± 35 nm; 62 particles measured). These new
supramolecular architectures contain narrow size distributions and uniform structures, in
good agreement with literature-reported results for achiral microcapsule analogues.21
The newly formed microcapsules contain a variety of features that make them particularly
amenable to supramolecular chiral catalysis, including: (a) multiple chiral centers,
covalently confined in a small space; (b) multiple amino groups that can be protonated or
deprotonated over a wide pH range;29 and (c) a hydrophobic core resulting from the
hydrophobic benzyl side chains.30
To investigate the effect of capsule formation on the resulting supramolecular chiral
environment, the newly synthesized chiral microcapsules were used as catalysts for the
transamination reaction of ketoacids to amino acids (Equation 2). Obtaining good
enantioselectivities in such transamination reactions has been an ongoing research
problem.10 Preliminary results indicate that the microcapsule-catalyzed reactions proceeded
with significantly higher enantioselectivities compared to the polymer-catalyzed reactions
(up to 20% enantiomeric excess (ee) obtained for the synthesis of L-valine, under conditions
where the polymer itself yielded 4% ee). Efforts to optimize the reaction conditions are in
progress.
Interestingly, the chiral PEIs also functioned as efficient siRNA delivery agents. Although
there are many reported examples of PEIs used for siRNA and DNA delivery,31–33 many of
these delivery vehicles suffer from high cytotoxicity.34 The development of gene delivery
agents that are both effective and less toxic remains a highly relevant research objective.
The following 4 polymers were investigated as potential siRNA delivery agents: R-2a-13;
S-2a-13; R-6-13; and S-6-13, where the R/S designation refers to the chirality of the side
chain and the number 13 refers to the number of repeat units in the polymers. The efficacy
of these polymers in transfecting an Alexa488-labeled control siRNA sequence35 to Huh7
cells36 was measured by determining the intracellular fluorescence 24 hours post-
transfection. The results obtained using the chiral polyamines were compared to results
obtained using commercially available transfection reagents: Genjet siRNA Transfection
Reagent (SignaGen Laboratories); HiPerFect Transfection Reagent (Qiagen Laboratories);37
and Lipofectamine 2000 (Invitrogen Technologies).38
Figure 2 shows a graph of the intracellular fluorescence of Huh7 cells following their
incubation with Alexa-labeled siRNA with various delivery reagents. The intracellular
fluorescence obtained with compounds S-6-13 and S-2a-13 is substantially higher than the
fluorescence observed with positive controls Lipofectamine and Genjet, indicating the
polymers’ ability to transfect siRNA efficiently (Table 1). More interestingly, compounds
R-2a-13 and R-6-13, which are identical except for the three-dimensional configuration of
the benzyl group, transfect siRNA with approximately the same efficiency as Lipofectamine
and Genjet, and substantially lower than the “enantiomeric” polymers.
The chirality of the side chains of the PEIs thus has a direct and measurable effect on the
ability of PEIs to transfect siRNA efficiently: S chiral centers (compounds S-6-13 and
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S-2a-13) transfect siRNA more efficiently than the R analogues. Such a result may seem
intuitive: that the interaction of two chiral macromolecules (chiral PEI and chiral siRNA)
depends on the three-dimensional configuration of both molecules. This intuition is borne
out by the results of this study, which is the first direct proof that the chirality of a
polyamine directly impacts its transfection efficiency. Similar effects of the chirality on
transfection efficiency were recently observed for the lipid delivery agent 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP).39 In that report, the R enantiomer performed better
than either the S enantiomer or the racemic DOTAP mixture.
The toxicity of the newly synthesized PEIs was tested using an MTT assay.40 After 24 hours
of incubation, the absorbance of the cells was quantified and the cell viability was
calculated. Using 1000 nM of S-2a-13 reduced the cell viability to 88%, and 1000 nM of
S-6-13 reduced it to 82%. By comparison, Lipofectamine reduced cell viability to 89%, and
compounds R-2a-13 and R-6-13 reduced viability to 78% and 71%. Thus, the toxicity of the
chiral PEIs, like the transfection efficiency, depends on the three-dimensional configuration
of the benzylic side chains.
The differences in transfection efficiency and toxicity mean that the S- and R-configured
PEIs likely have fundamentally different three-dimensional architectures. The relationship
between the chirality of individual stereocenters and the overall polymer configuration has
been studied for related polymers using circular dichroism spectroscopy.41–43 These
differences in chirality affect the polymers’ solubility44 and their interactions with DNA,45
and as shown here, their transfection efficiencies.
In summary, chiral polymers 6 and 2a were synthesized via straightforward, well-
precedented procedures. These polymers were used for two novel applications: the
fabrication of chiral, covalently-linked microcapsules, and the transfection of siRNA to
Huh7 cells. The chiral microcapsules can be used for a number of potential applications in
supramolecular chiral catalysis and in supramolecular enantiomer separations. The chirality-
dependent siRNA transfection also provides an intriguing platform for further investigation.
In particular, polymer S-2a-13 demonstrated good transfection efficiency and limited
toxicity, and will be used for further biochemical investigations. The results of these and
other experiments will be reported in due course.
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TEM images of chiral microcapsules 8 (Blue line represents a 500 nm scale)
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Chart of the intracellular fluorescence of Huh7 cells after transfection with siRNA (all PEIs
were used at a 1000 nM final concentration)
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General synthetic methods for linear and branched polyethyleneimine (PEI)
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Synthesis of chiral polymers 2a
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Synthesis of chiral covalently-linked microcapsules
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Enantioselective transamination of ketoacids 9 to amino acids 11
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Table 1
Transfection efficiencies of chiral PEIs and commercial transfection agents
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